TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17880369
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g agar
Study: 17880369
Drug: 5.2 g
Normalized name: Veltassa 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.2 g pectin
Study: 11257337
Drug: CAIV-T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAIV-T vaccine
Study: 22324182
Drug: Systemic family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic family therapy (SB; exclusively verbal)
Study: 19415994
Drug: Levothyroxine (LT(4))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (LT(4)) treatment in OH group
Study: 10921125
Drug: Abstinence capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence capsule
Study: 23996473
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous (iv) doses of blosozumab up to 750 mg
Study: 23996473
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous (sc) doses of blosozumab 150 mg
Study: 22024822
Drug: Intravenous doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous doxycycline (40 to 200 mg)
Study: 22024822
Drug: Doxycycline (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (intravenous and oral)
Study: 20716558
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) alone
Study: 20716558
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clomiphene citrate (CC) plus metformin
Study: 10071274
Drug: 8-in-1 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-in-1 chemotherapy before and after XRT
Study: 7570323
Drug: OLT candidates
Normalized name: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
DrugBank: FINLAY-FR-1 (DB16524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLT candidates after volume infusion (1 L of crystalloid)
Study: 12777271
Drug: Long-acting risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting risperidone 25 mg
Study: 12777271
Drug: Long-acting risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting risperidone 50 mg
Study: 16965196
Drug: Long-acting risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting risperidone 25 mg and 50 mg
Study: 8986186
Drug: Intra-articular tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular tenoxicam 20 mg in 20 ml of normal saline
Study: 23489210
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg zanamivir
Study: 23489210
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg zanamivir
Study: 19562574
Drug: 32 g
Normalized name: PEG-32 Glyceryl Laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 g liquorice alone for 2 weeks
Study: 19562574
Drug: 32 g
Normalized name: PEG-32 Glyceryl Laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 g liquorice combined with 25 mg hydrochlorothiazide for 2 weeks
Study: 7852228
Drug: Aspirin 325mg
Normalized name: ASPIRIN 325MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325mg (group A, n = 12)
Study: 7852228
Drug: Aspirin 160mg
Normalized name: Premier Value Jr. Non-Aspirin 160mg Quick Melt (Grape)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 160mg (group B, n = 16)
Study: 2894232
Drug: Aspirin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (both doses)
Study: 2508483
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (DA) infusion at 2.5 micrograms.kg‐1.min‐1
Study: 2508483
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (DA) infusion at 10 micrograms.kg‐1.min‐1
Study: 16822105
Drug: 12-session group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-session group cognitive-behavioral therapy (CBT)
Study: 10512903
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen treatment (100% oxygen, 3 L/min) for 24 hours among patients with SSS scores of <40
Study: 7793298
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity in non-obese FH subgroup
Study: 7793298
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between insulin and BMI
Study: 7793298
Drug: Hormonal parameters
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal parameters including insulin
Study: 2029134
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of flucloxacillin and metronidazole
Study: 7270617
Drug: Intrauterine irrigation
Normalized name: Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine irrigation with normal saline solution
Study: 24927436
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without probiotics
Study: 29659416
Drug: PICU Soothing
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICU Soothing intervention (parental comforting with touch and reading, followed by music via soft headbands, administered once daily throughout hospitalization)
Study: 10629708
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy or hormone therapy with tamoxifen
Study: 7782525
Drug: Pulsed Nd:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd: YAG laser treatment (113 mJ pulses at 15 pulses s‐1 for 3 min)
Study: 30346026
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (N2 O) inhalation
Study: 30188494
Drug: Low Exposure
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Exposure (250 μg/m)
Study: 30188494
Drug: High Exposure
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Exposure (500 μg/m)
Study: 22162541
Drug: MK-5046 (10-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5046 (10-160 mg)
Study: 20306334
Drug: Spoon administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spoon administration of Oral Rehydration Solutions (ORS)
Study: 20306334
Drug: Nasogastric tube
Normalized name: nasogastric tube
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasogastric tube administration of Oral Rehydration Solutions (ORS)
Study: 17608314
Drug: Low-dose methylphenidate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylphenidate (0.3 mg/kg/dose)
Study: 17608314
Drug: High-dose methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylphenidate (0.5 mg/kg/dose)
Study: 15651051
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (1000 mg)
Study: 15651051
Drug: Lithium (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (900 mg)
Study: 12393361
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 30 mg kg(‐1) as a bolus before induction and 10 mg kg(‐1) h(‐1) by continuous i.v. infusion during the operation
Study: 15653705
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (isotonic solution)
Study: 1719729
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (infusion of Ringer lactate)
Study: 30442251
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg kg‐1 S-ketamine
Study: 30442251
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg‐1 S-ketamine
Study: 16372229
Drug: hGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH treatment for 24 months
Study: 2684383
Drug: Doxorubicin (DX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DX) 75 mg/m2 IV every 3 weeks
Study: 2684383
Drug: Idarubicin (IDA)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDA) 45 mg/m2 orally every 3 weeks
Study: 27645465
Drug: Chiropractic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic manipulative therapy (CMT) - four treatments over 2 weeks
Study: 27645465
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group - no treatment
Study: 22302849
Drug: Fixed-dose artesunate-amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed-dose artesunate-amodiaquine regimen
Study: 23248072
Drug: Opicapone 25
Normalized name: opicapone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 25 mg
Study: 28240566
Drug: Bayesian adaptive
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian adaptive randomization treatment regimens
Study: 23826760
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of oral sodium bicarbonate with a serum target HCO3- level of 24±1 mmol/L
Study: 23826760
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy of sodium bicarbonate with a serum target level of 20±1 mmol/L
Study: 23826760
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of oral sodium bicarbonate
Study: 23826760
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy of sodium bicarbonate
Study: 16877721
Drug: rhEndostatin administered
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhEndostatin administered as a bid subcutaneous injection at a starting dose of 60 mg/m2/d, escalated to 90 mg/m2/d if necessary
Study: 18184901
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg
Study: 11386930
Drug: Intravenous alpha‐gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alpha‐gal A (0.2 mg/kg every other week for 12 doses)
Study: 6403000
Drug: Oral neomycin
Normalized name: neomycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neomycin and erythromycin base plus parenteral placebo
Study: 6403000
Drug: Oral neomycin
Normalized name: neomycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neomycin and erythromycin base plus parenteral cephalothin sodium
Study: 28283937
Drug: Bisphosphonate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate treatment initiated at 2 weeks after hemiarthroplasty
Study: 2911877
Drug: Supine position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine position with 1 mg bumethanide intravenously
Study: 2911877
Drug: Upright position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upright position with 1 mg bumethanide intravenously
Study: 381093
Drug: Antacid
Normalized name: Antacid
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid
Study: 31417013
Drug: Targeted antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotics (TA) based on rectal swab culture
Study: 31417013
Drug: Empirical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antibiotics (EA) - standard parenteral ciprofloxacin
Study: 28099054
Drug: Noninvasive interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Noninvasive interventions (e.g., blood cultures, medications, imaging)
Study: 28099054
Drug: Aggressive or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive or invasive options (e.g., dialysis, bronchoscopy, surgical consultation, transfer to ICU)
Study: 25853370
Drug: Methamphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (10 mg or 20 mg)
Study: 15181049
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg daily for 6 weeks)
Study: 9483215
Drug: Sex hormones
Normalized name: GENITO URINARY SYSTEM AND SEX HORMONES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormones
Study: 3520315
Drug: Hydralazine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (300 mg per day) and Isosorbide dinitrate (160 mg per day)
Study: 3520315
Drug: Prazosin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (20 mg per day)
Study: 29861260
Drug: Intensified active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified active treatment with additional mobilization and strength training
Study: 23230745
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of low dose (0.5 g) cefozopran hydrochloride
Study: 23230745
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of middle dose (1.0 g) cefozopran hydrochloride
Study: 23230745
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of high dose (2.0 g) cefozopran hydrochloride
Study: 16104440
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration with bupivacaine and pre-incisional intramuscular (IM) ketorolac (group BK)
Study: 7566405
Drug: Gammaglobulin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gammaglobulin (10 g doses at 3-day intervals)
Study: 7235737
Drug: Oral retinoid
Normalized name: tretinoin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral retinoid Ro 10‐9359 (75 mg/d)
Study: 25597699
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (240 mg)
Study: 25597699
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng (1200 mg)
Study: 21832958
Drug: CNI standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI standard therapy
Study: 17907113
Drug: Pioglitazone (30-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30-45 mg/day)
Study: 15889234
Drug: Gliclazide (80-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (80-320 mg/day)
Study: 9530343
Drug: Aphidicolin (APC)
Normalized name: Recombinant human activated protein C (rH-APC)
DrugBank: Aphidicolin (DB17742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aphidicolin (APC) treatment in PHA-stimulated lymphocyte cultures
Study: 9530343
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no APC treatment)
Study: 2587826
Drug: Concurrent instruction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent instruction (two sessions per day, random presentation of two words)
Study: 26328624
Drug: OM3‐CA 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3‐CA 4 g/d
Study: 26328624
Drug: Control (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (olive oil, OO) 4 g/d
Study: 15074449
Drug: Cessation services
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cessation services received by smokers with COPD (advised to quit, prescribed nicotine patches, referred to a smoking cessation program)
Study: 8874076
Drug: polyI:polyC12U (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: polyI:polyC12U (400 or 700 mg) with zidovudine
Study: 1502478
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg twice daily for 6 months
Study: 1502478
Drug: Prior omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior omeprazole therapy
Study: 30962264
Drug: Dexmedetomidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.4 μg/(kg · min) for 10 min before surgery
Study: 27312678
Drug: Remote limb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote limb ischemic conditioning (RLIC) once daily for 12 months, consisting of five cycles of 5 min of pressure treatment at 200 mm Hg, followed by 5 min of reperfusion.
Study: 27312678
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment once daily for 12 months, consisting of five cycles of 5 min of pressure treatment at 60 mm Hg, followed by 5 min of reperfusion.
Study: 20364590
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (120 mg/d for 8 weeks)
Study: 19091199
Drug: Pio+Met (pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pio+Met (pioglitazone plus metformin)
Study: 10831027
Drug: pindolol 2.5
Normalized name: pindolol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol 2.5 mg three times daily
Study: 10831027
Drug: placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo three times daily
Study: 9091392
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) 5.9 g/d
Study: 9091392
Drug: Control (stools
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (stools collected at least 24 h after the last fecal excretion of PEG)
Study: 12682802
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg four times daily for 7 days
Study: 26636422
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of febuxostat 80 mg
Study: 26636422
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of febuxostat 40 mg
Study: 26636422
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of febuxostat 80 mg
Study: 29606665
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) monotherapy
Study: 27175292
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) + Methotrexate (MTX) combination therapy
Study: 21997881
Drug: Flaxseed pillow
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed pillow treatment
Study: 14614003
Drug: Intraperitoneal (i.p.)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (i.p.) administration of Flt3-L (25 micro g/kg, maximum 1500 micro g), days 1-5 and 8-12, then changed to subcutaneous (s.c.) at 4 weeks.
Study: 14614003
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) administration of Flt3-L (25 micro g/kg, maximum 1500 micro g), days 1-5 and 8-12, then changed to intraperitoneal (i.p.) at 4 weeks.
Study: 14614003
Drug: Both i.p.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both i.p. and s.c. administration of Flt3-L.
Study: 6827423
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (albuterol)
Study: 7574130
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine
Study: 26471212
Drug: Dextromethorphan/quinidine (DM/Q)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan/quinidine (DM/Q) 20/10 mg twice daily
Study: 22192488
Drug: Twice-yearly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-yearly treatment
Study: 11881868
Drug: Peribulbar block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar block with 5 ml of 1:1 mixture of 0.5% plain bupivacaine and 2% lignocaine supplemented with hyaluronidase 300 i.u. ml(‐1)
Study: 11881868
Drug: Deep topical
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep topical fornix nerve block anaesthesia (DTFNBA) with placement of a sponge soaked in 0.5% bupivacaine deep into the conjunctival fornices for 15 min
Study: 10211536
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg (Control)
Study: 10211536
Drug: Lovastatin 10
Normalized name: lovastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 10 mg
Study: 2611069
Drug: Fluid preloading
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid preloading with 1 litre of crystalloid fluid given at a rate of 1000 ml in 15 min before spinal anaesthesia
Study: 2611069
Drug: No preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preload group (1 ml min‐1 fluid rate)
Study: 328335
Drug: Sexual steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual steroids (Estrovis 4000)
Study: 30977980
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet administration
Study: 26610558
Drug: TheaTrim (Purus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TheaTrim (Purus Labs; containing a branded form of theacrine (Teacrine™) and caffeine (150 mg))
Study: 26610558
Drug: Caffeine only
Normalized name: Caffeine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine only (150 mg)
Study: 10586394
Drug: Linezolid 375
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 375 mg
Study: 7537913
Drug: Newer agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer agents (Paclitaxel, Docetaxel, Vinorelbine, Amonafide)